Adesh Kaul
Director of Finance/CFO at BASILEA PHARMACEUTICA AG
Net worth: 20 900 $ as of 2024-03-30
Profile
Adesh Kaul is currently working as the Chief Financial Officer at Basilea Pharmaceutica AG since 2019.
Previously, he worked as a Research Analyst at NZB Neue Zürcher Bank AG (Investment Management) and also held the position of CFO & Head-Corporate Development at Spexis Ltd.
from 2015 to 2016.
He also worked as a Research Analyst at NZB Neue Zürcher Bank AG.
Mr. Kaul holds an MBA from the University of St. Gallen and a graduate degree from the University of Basel.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
BASILEA PHARMACEUTICA AG
0.00% | 2022-12-30 | 500 ( 0.00% ) | 20 900 $ | 2024-03-30 |
Adesh Kaul active positions
| Companies | Position | Start |
|---|---|---|
| BASILEA PHARMACEUTICA AG | Director of Finance/CFO | 2019-04-09 |
Former positions of Adesh Kaul
| Companies | Position | End |
|---|---|---|
| SPEXIS AG | Director of Finance/CFO | 2015-12-31 |
NZB Neue Zürcher Bank AG (Investment Management)
 NZB Neue Zürcher Bank AG (Investment Management) Major BanksFinance NZB Neue Zürcher Bank AG/Investment Management (NZB-IM) is the investment management division of NZB Neue Zürcher Bank AG, in turn a subsidiary of Bank Sarasin & Cie AG. The activities of NZB Neue Zürcher Bank AG include brokerage, asset management and investment advisory services. Founded in 2000, the firm is based in Zurich, Switzerland. Clients include institutional investors and private individuals from Switzerland and worldwide. NZB-IM managed a Swiss-domiciled fund until 2009 when they ceased their asset management activities. | Analyst-Equity | - |
NZB Neue Zürcher Bank AG
 NZB Neue Zürcher Bank AG Investment Banks/BrokersFinance NZB Neue Zürcher Bank AG is a majority-owned subsidiary of MainFirst Schweiz AG, itself a subsidiary of MainFirst Holding AG in Switzerland. Founded in 2000 and based in Zurich, NZB absorbed the brokerage business of Bank Sarasin & Cie AG in 2007, which led Bank Sarasin to hold a 40% stake in NZB. In 2009 they increased their shareholding to a majority interest. NZB Neue Zürcher Bank AG provides primarily brokerage services. Up until 2009 they also had an asset management and investment advisory department. Their clients include Swiss and international institutional investors as well as private individuals. | Analyst-Equity | - |
Training of Adesh Kaul
| University of St. Gallen | Masters Business Admin |
| University of Basel | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| BASILEA PHARMACEUTICA AG | Health Technology |
| SPEXIS AG | Health Technology |
| Private companies | 2 |
|---|---|
NZB Neue Zürcher Bank AG (Investment Management)
NZB Neue Zürcher Bank AG (Investment Management) Major BanksFinance NZB Neue Zürcher Bank AG/Investment Management (NZB-IM) is the investment management division of NZB Neue Zürcher Bank AG, in turn a subsidiary of Bank Sarasin & Cie AG. The activities of NZB Neue Zürcher Bank AG include brokerage, asset management and investment advisory services. Founded in 2000, the firm is based in Zurich, Switzerland. Clients include institutional investors and private individuals from Switzerland and worldwide. NZB-IM managed a Swiss-domiciled fund until 2009 when they ceased their asset management activities. | Finance |
NZB Neue Zürcher Bank AG
NZB Neue Zürcher Bank AG Investment Banks/BrokersFinance NZB Neue Zürcher Bank AG is a majority-owned subsidiary of MainFirst Schweiz AG, itself a subsidiary of MainFirst Holding AG in Switzerland. Founded in 2000 and based in Zurich, NZB absorbed the brokerage business of Bank Sarasin & Cie AG in 2007, which led Bank Sarasin to hold a 40% stake in NZB. In 2009 they increased their shareholding to a majority interest. NZB Neue Zürcher Bank AG provides primarily brokerage services. Up until 2009 they also had an asset management and investment advisory department. Their clients include Swiss and international institutional investors as well as private individuals. | Finance |
- Stock Market
- Insiders
- Adesh Kaul
